Stocks · Healthcare · Medical - Specialties
Standard BioTools Inc. LAB
$0.74 +2.25% Close, Oct 2, 2026 · NASDAQ · Market cap $291.5M
Weak trend
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -94.8% from -84.1% a year earlier.
- Revenue over the last four quarters was $84.6M, down 36.7% from a year earlier.
- The stock is 56% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 13%
- Revenue growth, 3-year CAGRBottom 16%
- Revenue growth accelerationBottom 42%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 41%
- Gross marginBottom 33%
- Operating marginBottom 29%
- Accruals (lower is better)Bottom 20%
- Interest coverBottom 2%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 23%
- Free-cash-flow yieldBottom 18%
- EBITDA / enterprise valueBottom 2%
- Sales / enterprise valueTop 5%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 8%
- 6-month returnBottom 25%
- 1-year return vs S&P 500Bottom 14%
- Distance from 52-week highBottom 20%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 12%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 25%
- Upside to consensus price targetTop 9%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 47%
- Maximum drawdown, 3 yearsBottom 37%
- Beta vs S&P 500 (lower is better)Bottom 31%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -35.8% | -36.7% | ↓ |
| Gross margin | 50.0% | 49.1% | ↓ |
| Operating margin | -84.1% | -94.8% | ↓ |
| FCF margin | -78.9% | -97.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -36.7% | -35.8% | ↓ | Bottom 13% |
| Gross margin | 49.1% | 50.0% | ↓ | Bottom 33% |
| Operating margin | -94.8% | -84.1% | ↓ | Bottom 29% |
| Net margin | -103.3% | -90.1% | ↓ | — |
| Free-cash-flow margin | -97.6% | -78.9% | ↓ | — |
| Return on invested capital | -8.3% | — | Top 41% | |
| Revenue growth, 3-year CAGR | -4.5% | — | Bottom 16% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 30.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +44.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -5346.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.29%
- Shareholder yield
- -0.29%
- Share count change, 1 year
- +2.7%
- Share count change, 3-year CAGR
- +70.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -64.2%
- Average 2-day reaction, last 8
- -1.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $3.25
- Target vs current price
- +336.4%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 60%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -449.0% | -4.4% | -4.0% | -20.7% | — |
| May 5, 2026 | +0.0% | +4.7% | +5.9% | +24.1% | -4.0% |
| Feb 24, 2026 | +300.0% | +3.6% | -0.9% | -12.3% | -9.9% |
| Nov 4, 2025 | -107.7% | -4.0% | -5.6% | +14.5% | +12.9% |
| Aug 11, 2025 | +0.0% | -2.3% | -6.1% | +3.8% | -5.3% |
| May 6, 2025 | +0.0% | -7.8% | +0.9% | -7.0% | +15.7% |
| Feb 26, 2025 | +28.6% | -7.1% | -15.9% | -7.9% | -17.5% |
| Oct 30, 2024 | +37.5% | +7.4% | +20.6% | -2.3% | -5.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.07 | -$0.01 | -449.0% | $20.1M |
| May 5, 2026 | -$0.02 | -$0.02 | +0.0% | $21.1M |
| Feb 24, 2026 | $0.06 | -$0.03 | +300.0% | $23.8M |
| Nov 4, 2025 | -$0.09 | -$0.04 | -107.7% | $19.6M |
| Aug 11, 2025 | -$0.04 | -$0.04 | +0.0% | $21.8M |
| May 6, 2025 | -$0.04 | -$0.04 | +0.0% | $40.8M |
| Feb 26, 2025 | -$0.05 | -$0.07 | +28.6% | $46.7M |
| Oct 30, 2024 | -$0.05 | -$0.08 | +37.5% | $45.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 0.59× | — | — | Top 5% |
| Free-cash-flow yield | -28.33% | — | — | Bottom 18% |
| Earnings yield | -30.95% | — | — | Bottom 23% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 1
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.6%
- 200-day average slope (20 days)
- -6.4%
- Distance from 50-day average
- +1.6%
- Distance from 200-day average
- -25.2%
- RSI (14)
- 54.6
- Relative volume
- 0.64×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 57.3%
- Volatility vs own 5-year history
- 22th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.50
- Correlation with S&P 500
- 0.35
- Current drawdown from 1-year high
- -55.7%
- Maximum drawdown, 3 years
- -78.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 5, 2020 | Aug 28, 2026 | -92.6% | 1481 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $291.5M
- EPS, diluted (TTM)
- -$0.23
- Revenue (TTM)
- $84.6M
- 52-week range
- $0.63 – $1.72
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $130.6M | $97.9M | $106.3M | $174.4M | $85.3M |
| Gross profit | $69.4M | $37.1M | $50.5M | $84.3M | $42.5M |
| Operating income | -$67.5M | -$116.2M | -$76.6M | -$175.2M | -$93.3M |
| Net income | -$59.2M | -$190.1M | -$74.7M | -$138.9M | -$74.9M |
| EPS (diluted) | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.0M | $46.7M | $20.2M | $21.8M | $19.6M | $23.8M | $21.1M | $20.1M |
| Net income | -$26.9M | -$34.1M | -$26.0M | -$33.5M | -$34.7M | $19.3M | -$45.2M | -$26.8M |
| EPS (diluted) | -$0.07 | -$0.09 | -$0.07 | -$0.09 | -$0.09 | $0.05 | -$0.12 | -$0.07 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$44.1M | -$89.4M | -$43.3M | -$143.5M | -$74.3M |
| Capital expenditure | -$13.3M | -$3.8M | -$2.8M | -$8.4M | -$8.3M |
| Free cash flow | -$57.3M | -$93.2M | -$46.1M | -$151.8M | -$82.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$1.8M | -$774,000 | -$5.4M | -$40.9M | $1.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $476.7M
- Total assets
- $627.2M
- Total liabilities
- $87.2M
- Total debt
- $28.1M
- Net debt
- -$241.9M
- Shareholders’ equity
- $540.0M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 2,593,308
- Days to cover
- 1.44
- Change vs previous report
- -13.0%
FINRA short interest, settlement date Sep 15, 2026.